The molecular analysis of breast cancer utilizing targeted nanoparticle based ultrasound contrast agents

Technology in Cancer Research and Treatment

Volumn 4, Issue 6, 2005, Pages 627-636

  Sakamoto, Jason H ^a,b   Smith, Bryan R ^a,b   Xie, Bin ^b   Rokhlin, Stanislav I ^b   Lee, Stephen C ^a,b   Ferrari, Mauro ^b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

And Nanoparticle; Breast cancer; Contrast agent; HER 2 neu; SKBR 3; Ultrasound

Indexed keywords

AGAROSE; CONTRAST MEDIUM; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IRON OXIDE; MEMBRANE RECEPTOR; NANOPARTICLE; TRASTUZUMAB;

ALGORITHM; ARTICLE; BREAST CANCER; CONJUGATION; DIAGNOSTIC VALUE; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MECHANICS; ONCOGENE NEU; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; ULTRASOUND;

EID: 30544444954     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460500400606     Document Type: Article

References (37)

1. H. K. W. Koeppen, B. D. Wright, A. D. Burt, P. Quirke, A. M. McNicol, N. O. Dybdal, M. X. Sliwkowski, and K. J. Hillan. Overexpression of HER2/neu in Solid Tumours: An Immunohistochemical Survey. Histopathology 38, 96-104 (2001).
2. N.E. Hynes and D. F. Stern. The Biology of erbB-2/neu/HER-2 and its Role in Cancer. Biochim Biophys Acta. 1198, 165-84 (1994).
3. A. Paradiso, E. Marubini, P. Verderio, F. D. Paola, R. Silvestrini, G. Simone, F. Marzullo, S. Menard, E. Tagliabue, G. Tomasich, M. Mottolese, P. Querzoli, G. Bevilacqua, A. Granato, E. Marinaro, S. Folicaldi, N. Naldi, V. Ludovini, P. Maioli, and L. Bernardi. Interobserver Reproducibility of Immunohistochemical HER-2/neu Evaluation in Human Breast Cancer: The Real-world Experience, International Journal of Biological Markers 19, 147-154 (2004).
4. I. F. Tannock and R. P. Hill, Eds. The Basic Science of Oncology. Third Ed. McGraw-Hill: New York (1998).
5. J. M. S. Bartlett, J. J. Going, E. A. Mallon, A. D. Watters, J. R. Reeves, P. Stanton, J. Richmond, B. Donald, R. Ferrier, and T. G. Cooke. Evaluating HER2 Amplification and Overexpression in Breast Cancer. Journal of Pathology 195, 422-428 (2001).
6. M. Pegram, G. Pauletti, and D. J. Slamon. HER-2/neu as a Predictive Marker of Response to Breast Cancer Therapy. Breast Cancer Research and Treatment 52, 65-77 (1998).
7. R. Cotran, V. Kumar, and T. Collins. Pathologic Basis of Disease. 6th Ed. pp. 260-328. Philadelphia: W.B. Saunders (1999).
8. S. Masood and M. M. Bui. Prognostic and Predictive Value of HER2/neu Oncogene in Breast Cancer. Microscopy Research and Technique 59, 102-108 (2002).
9. S. Menard, E. Tagliabue, M. Campiglio, and S. M. Pupa. Role of HER2 Gene Overexpression in Breast Carcinoma. Journal of Cellular Physiology 182, 150-162 (2000).
10. R. M. Neve, H. A. Lane, and N. E. Hynes. The Role of Overexpressed HER2 in Transformation. Annals of Oncology 12, S9-S13 (2001).
11. D. J. Slamon, W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, W. J. Levin, S. G. Stuart, J. Udove, A. Ullrich, and M. F. Press. Studies of the HER-2/neu Proto-Oncogene in Human Breast and Ovarian Cancer. Science, New Series 244, 707-712 (1989).
12. M. F. Press, D. J. Slamon, M. Cobleigh, C. Vogel, J. Zhou, S. Anderson, G. Lieberman, and R. Mass. Improved Clinical Outcomes for Herceptin (R)-treated Patients Selected by Fluorescence In Situ Hybridization (FISH). Modern Pathology 15, 47A-47A (2002).
13. S. Vestey, C. Perks, C. Sen, C. Calder, J. Holly, and Z. Winters, Immunohistochemical Expression of Insulin-like Growth Factor Binding Protein-3 in Invasive Breast Cancers and Ductal Carcinoma In Situ: Implications for Clinicopathology and Patient Outcome. Breast Cancer Research 7, R119-R129 (2005).
14. R. Mass, M. F. Press, S. Anderson, and D. J. Slamon. Improved Survival Benefit from Herceptin (Trastuzumab) and Chemotherapy in Patients Selected by Fluorescence In Situ Hybridization. Breast Cancer Research and Treatment 69, 213-213 (2001).
15. C. Vogel, M. Cobleigh, D. Tripathy, J. Gutheil, L. Harris, L. Fehrenbacher, D. J. Slamon, M. Murphy, W. Novotny, M. Burchmore, S. Shak, S. Stewart, and M. F. Press. Efficacy and Safety of Trastuzumab as a Single Agent in First-line Treatment of HER2-overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology 20, 719-726 (2002).
16. P. Birner and G. Oberhuber. Is Fluorescence In Situ Hybridization Really Superior to HercepTest? Journal of Clinical Oncology 20, 4607-4609 (2002).
17. E. Elkin, M. Weinstein, E. Winer, K. Kuntz, S. Schnitt, and J. Weeks. HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis. Journal of Clinical Oncology 22, 854-863 (2004).
18. H. Yamashita, M. Nishio, T. Toyama, H. Sugiura, Z. Zhang, S. Kobayashi, and H. Iwase. Coexistence of HER2 Over-expression and p53 Protein Accumulation is a Strong Prognostic Molecular Marker in Breast Cancer. Breast Cancer Research 6, R-24-R30 (2004).
19. M. Hoang, A. Sahin, N. Ordonez, and N. Sneige. HER-2/neu Gene Amplification Compared with HER-2/neu Protein Overexpression and Interobserver Reproducibility in Invasive Breast Carcinoma. American Journal of Clinical Pathology 113, 852-859 (2000).
20. C. Hsu, D. Ho, C. Yang, C. Lai, I. YU, and H. Chiang. Interoberver Reproducibility of Her-2/neu Protein Overexpression in Invasive Breast Carcinoma Using the DAKO HerceoTest. American Journal of Clinical Pathology 118, 693-698 (2002).
21. T. Thomson, M. Hayes, J. Spinelli, E. Hilland, C. Sawrenko, D. Phillips, B. Dupuis, and R. Parker. HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization. Modern Pathology 14, 1079-1086 (2001).
22. H. Tsuda, F. Akiyama, H. Terasaki, T. Hasegawa, M. Kurosumi, M. Shimadzu, S. Yamamori, and G. Sakamoto. Detection of HER-2/neu (c-erb B2) DNA Amplifications in Primary Breast Carcinoma. Interobserver Reproducibility and Correlation with Immunohistochemical HER-2 Overexpression. Cancer 92, 2965-2974 (2001).
23. A. Rhodes, B. Jasani, E. Anderson, A. Dodson, and A. Balaton. Evaluation of HER-2/neu Immunohistochemical Assay Sensitivity and Scoring on Formalin-fixed and Paraffin-processed Cell Lines and Breast Tumors: A Comparative Study Involving Results from Laboratories in 21 Countries. American Journal of Clinical Pathology 118, 408-417 (2002).
24. H. Verkooijen, J. Peterse, M. Schipper, E. Buskens, J. Hendriks, R. Pijnappel, P. Peeters, B. Rinkes, W. Mali, and R. Holland. Interobserver Variability Between General and Expert Pathologists During the Histopathological Assessment of Large-core Needle and Open biopsies of Non-palpable Breast Lesions. European Journal of Cancer 39, 2187-2191 (2003).
25. M. Piver, Y. Tsukada, B. Werness, R. DiCioccio, A. Whittemore, and B. Ponder. Comparative Study of Ovarian Cancer Histopathology by Registry Pathologists and Referral Pathologists: A Study by the Gilda Radner Familial Ovarian Cancer Registry. Gynecologic Oncology 78, 166-170 (2000).
26. R. Schlemper, S. Dawsey, M. Itabashi, A. Iwashita, Y. Kato, M. Koike, K. Lewin, R. Riddell, T. Shimoda, P. Sipponen, M. Stolte, and H. Watanabe. Differences in Diagnostic Criteria for Esophageal Squamous Cell Carcinoma Between Japanese and Western Pathologists. Cancer 88, 996-1006 (2000).
27. B. Dunne and J. J. Going. Scoring Nuclear Pleomorphism in Breast Cancer. Histopathology 39, 259-265 (2001).
28. H. Tsuda, H. Sasano, F. Akiyama, M. Kurosumi, T. Hasegawa, R. Osamura, and G. Sakamoto. Evaluation of Interobserver Agreement in Scoring Immunohistochemical Results of HER-2/neu (c-erbB-2) Expression Detected by HercepTest, Nichirei Polyclonal Antibody, CB11 and TAB250 in Breast Carcinoma. Pathology International 52, 126-134 (2002).
29. J. Liu and M. Ferrari. Mechanical Spectral Signatures of Malignant Disease? A Small-Sample, Comparative Study of Continuum vs. Nano-Biomechanical Data Analyses. Disease Markers 18, 175-183 (2002).
30. J. Liu and M. Ferrari. A Discrete Model for the High Frequency Elastic Wave Examination on Biological Tissue. CMES 4, 421-430 (2003).
31. M. Ferrari. Nanomechanics and Biomedical Nanomechanics: Eshelby's Inclusion and Inhomogeneity Problems at the Discrete/Continuum Interface. Biomedical Microdevices 2, 273-281 (2000).
32. J. Liu. A Nanomechanical Approach for Ultrasonic Tissue Analysis, in Biomedical Engineering. The Ohio State University: Columbus (2002).
33. J. A. Copland, M. Eghtedari, V. L. Popov, N. Kotov, N. Mamedova, M. Motamedi, and A. A. Oraevsky. Bioconjugated Gold Nanoparticles as a Molecular Based Contrast Agent: Implications for Imaging of Deep Tumors Using Optoacoustic Tomography. Mol. Imaging Biol. 6, 341-349 (2004).
34. P. K. Smith, R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson, and D. C. Klenk. Measurement of Protein Using Bicinchoninic Acid. Anal Biochem. 150, 76-85 (1985).
35. J. Riemer, H. H. Hoepken, H. Czerwinska, S. R. Robinson, and R. Dringen. Colorimetric Ferrozine-based Assay for the Quantitation of Iron in Cultured Cells. Anal Biochem. 331, 370-375 (2004).
36. L. Wang, B. Xie, and S. I. Rokhlin. Determination of Embedded Layer Properties Using Adaptive Time-frequency Domain Analysis. J. Acoust. Soc. Am. 111, 2644-2653 (2002).
37. A. Lavrentyev and S. I. Rokhlin. Determination of Elastic Moduli, Density, Attenuation, and Thickness of a Layer Using Ultrasonic Spectroscopy at Two Angles. J. Acoust. Soc. Am. 102, 3467-3477 (1997).